Select all docs (Max 200)
Narrow Results:
Publication Year
- 2024 50
Medical Subject
- Adolescent 1
- Adult 5
- Adverse Drug Reaction Reporting Systems 1
- Aged 1
- Alaska Natives 1
- American Indian or Alaska Native 1
- Chikungunya Fever/epidemiology 1
- Chikungunya Fever/prevention & Control 3
- Chikungunya Fever/prevention & control 1
- Child 1
- Cost-Benefit Analysis 5
- COVID-19 1
- COVID-19 Vaccines 7
- COVID-19 Vaccines/economics 1
- COVID-19/prevention & control 6
- COVID-19/prevention & Control 1
- Decision Making 4
- Dengue/prevention & control 2
- Dengue Vaccines 2
- GRADE Approach 4
- Guillain-Barre Syndrome 1
- Hospitalization 1
- Indians, North American 1
- Infant 2
- Infant, Low Birth Weight 1
- Infant, Newborn 6
- Infant, Premature 1
- Infant Mortality 1
- Influenza, Human/prevention & Control 1
- Influenza/prevention & control 3
- Influenza in Birds 1
- Influenza Vaccines 4
- Laboratory Infection/prevention & Control 3
- Laboratory Personnel 3
- Medication Errors 1
- Meningitis, Meningococcal/epidemiology 1
- Meningitis, Meningococcal/prevention & control 3
- Meningococcal Infections/prevention & control 1
- Meningococcal Vaccines 3
- nfluenza A Virus, H5N1 Subtype 1
- Papillomavirus Infections/prevention & control 1
- Papillomavirus Vaccines 1
- Patient Safety 1
- Pneumococcal Infections/prevention & control 4
- Pneumococcal Vaccines 4
- Pregnancy 2
- Pregnant Women 2
- Respiratory Syncytial Virus, Human 9
- Respiratory Syncytial Virus Infections/drug therapy 2
- Respiratory Syncytial Virus Infections/prevention & control 13
- Respiratory Syncytial Virus Infections/prevention & Control 6
- Respiratory Syncytial Virus Vaccines 3
- Respiratory Syncytial Virus Vaccines/adverse Effects 10
- Respiratory Syncytial Virus Vaccines/economics 4
- Risk Assessment 2
- Safety 1
- SARS-CoV-2 1
- Vaccination 24
- Vaccination/adverse Effects 1
- Vaccines 23
- Vaccines, Conjugate 3
- Vaccines/adverse Effects 1
- Viral Vaccines 4
Personal Author
- Adhikari, Bishwa B. 1
- Bergren, Nicholas 1
- Blanton, Lenee 1
- Britton, Amadea 2
- Brooks, Oliver 1
- Chen, Wilbur 1
- Collins, Jennifer 1
- Daley, Matthew F. 1
- Das, Rituparna 1
- Donahue, Jim 1
- Duffy, Jonathan 1
- Dugan, Vivien G. 1
- Ferdinands, Jill 1
- Gebremariam, Acham 1
- Gerber, Susan 1
- Grohskopf, Lisa 1
- Havers, Fiona P. 1
- Hills, Susan 3
- Hills, Susan L. 1
- Hutton, David W. 3
- Janusz, Cara 1
- Jeon, Seonghye 1
- Jones, Jefferson 1
- Kilburn, Kelly 1
- Kobayashi, Miwako 1
- Kotton, Camille 1
- Leidner, Andrew 1
- Leidner, Andrew J. 1
- Lindsey, Nicole P. 1
- Link-Gelles, Ruth 2
- Lloyd, Patricia 1
- Loehr, James 1
- Loehr, Jamie 3
- Long, Sarah S. 1
- Melgar, Michael 2
- Meltzer, Martin I. 1
- Moro, Pedro L. 1
- Moulia, Danielle 1
- Munjal, Iona 1
- Nyamuswa, Christina 1
- Ortega-Sanchez, Ismael 1
- Ortega-Sanchez, Ismael R. 1
- Panagiotakopoulos, Lakshmi 1
- Payne, Amanda 1
- Pike, Jamie 1
- Prosser, Lisa A. 1
- Roper, Lauren 1
- Rose, Angela 1
- Rubis, Amy 1
- Saydah, Sharon 1
- Schillie, Sarah F. 1
- Shah, Melisa 1
- Sohn, Wendy 1
- Staples, J. Erin 1
- Stoecker, Charles 1
- Stokley, Shannon 2
- Surie, Diya 1
- Wallace, Megan 1
- Wong, Joshua 1
- Zhou, Fangjun 1
Corporate Author
- Centers for Disease Control and Prevention (U.S.) 3
- GSK Vaccines. 2
- Marshfield Clinic Research Institute 1
- Moderna (firm) 1
- National Center for Emerging and Zoonotic Infections (U.S.). Division of Vector-Borne Diseases. Dengue Branch. 1
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. 1
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases. Arboviral Diseases Branch. 3
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. 1
- National Center for Emerging Zoonotic and Infectious Diseases (U.S.) 1
- National Center for Immunization and Respiratory Diseases (U.S.) 4
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. 3
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Surveillance and Prevention Branch. RESP-NET Hospitalization Surveillance Team. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Vaccine Effectiveness Program. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. Applied Research, Implementation Science and Evaluation Branch. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. 2
- National Center for Immunizations and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. 1
- National Center for Immunizations and Respiratory Diseases (U.S.). Immunization Services Division. 2
- Pfizer Ltd. 1
- Sanofi AstraZeneca 1
- Tulane University. School of Public Health and Tropical Medicine. 1
- United States. Advisory Committee on Immunization Practices. 3
- United States. Advisory Committee on Immunization Practices. ACIP COVID-19 Vaccines Work Group. 1
- United States. Advisory Committee on Immunization Practices. Adult RSV Work Group. 3
- United States. Advisory Committee on Immunization Practices. Chikungunya Vaccines Work Group. 4
- United States. Advisory Committee on Immunization Practices. Hib/Meningococcal Vaccines Work Group. 2
- United States. Advisory Committee on Immunization Practices. HPV Vaccines Work Group. 1
- United States. Advisory Committee on Immunization Practices. Influenza Work Group. 1
- United States. Advisory Committee on Immunization Practices. Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group. 2
- United States. Advisory Committee on Immunization Practices. Meningococcal/Hib Vaccines Work Group. 1
- United States. Advisory Committee on Immunization Practices. Pneumococcal Vaccine Work Group. 1
- United States. Food and Drug Administration. Center for Biologics Evaluation and Research. Office of Biostatistics and Pharmacovigilance. 1
- University of Michigan. COVID-19 Vaccination Modeling Team. 1
- University of Michigan. School of Public Health. 2
Place as Subject
Resource Type General
- Agenda 6
- Presentation 41
- Press Release 3
Resource Type Specific
United States. Advisory Committee On Immunization Practices. Meeting (2024 June 26-28 : Atlanta, GA)
Select all docs (Max 200)
1 -
20 of 50 Results
SELECT A RANGE
SELECT A FORMAT
Refine Results
Refine Results:
- Adolescent (1)
- Adult (5)
- Adverse Drug Reaction Reporting Systems (1)
- Aged (1)
- Alaska Natives (1)
- American Indian or Alaska Native (1)
- Chikungunya Fever/epidemiology (1)
- Chikungunya Fever/prevention & Control (3)
- Chikungunya Fever/prevention & control (1)
- Child (1)
- Cost-Benefit Analysis (5)
- COVID-19 (1)
- COVID-19 Vaccines (7)
- COVID-19 Vaccines/economics (1)
- COVID-19/prevention & control (6)
- COVID-19/prevention & Control (1)
- Decision Making (4)
- Dengue/prevention & control (2)
- Dengue Vaccines (2)
- GRADE Approach (4)
- Guillain-Barre Syndrome (1)
- Hospitalization (1)
- Indians, North American (1)
- Infant (2)
- Infant, Low Birth Weight (1)
- Infant, Newborn (6)
- Infant, Premature (1)
- Infant Mortality (1)
- Influenza, Human/prevention & Control (1)
- Influenza/prevention & control (3)
- Influenza in Birds (1)
- Influenza Vaccines (4)
- Laboratory Infection/prevention & Control (3)
- Laboratory Personnel (3)
- Medication Errors (1)
- Meningitis, Meningococcal/epidemiology (1)
- Meningitis, Meningococcal/prevention & control (3)
- Meningococcal Infections/prevention & control (1)
- Meningococcal Vaccines (3)
- nfluenza A Virus, H5N1 Subtype (1)
- Papillomavirus Infections/prevention & control (1)
- Papillomavirus Vaccines (1)
- Patient Safety (1)
- Pneumococcal Infections/prevention & control (4)
- Pneumococcal Vaccines (4)
- Pregnancy (2)
- Pregnant Women (2)
- Respiratory Syncytial Virus, Human (9)
- Respiratory Syncytial Virus Infections/drug therapy (2)
- Respiratory Syncytial Virus Infections/prevention & control (13)
- Respiratory Syncytial Virus Infections/prevention & Control (6)
- Respiratory Syncytial Virus Vaccines (3)
- Respiratory Syncytial Virus Vaccines/adverse Effects (10)
- Respiratory Syncytial Virus Vaccines/economics (4)
- Risk Assessment (2)
- Safety (1)
- SARS-CoV-2 (1)
- Vaccination (24)
- Vaccination/adverse Effects (1)
- Vaccines (23)
- Vaccines, Conjugate (3)
- Vaccines/adverse Effects (1)
- Viral Vaccines (4)
- Adhikari, Bishwa B. (1)
- Bergren, Nicholas (1)
- Blanton, Lenee (1)
- Britton, Amadea (2)
- Brooks, Oliver (1)
- Chen, Wilbur (1)
- Collins, Jennifer (1)
- Daley, Matthew F. (1)
- Das, Rituparna (1)
- Donahue, Jim (1)
- Duffy, Jonathan (1)
- Dugan, Vivien G. (1)
- Ferdinands, Jill (1)
- Gebremariam, Acham (1)
- Gerber, Susan (1)
- Grohskopf, Lisa (1)
- Havers, Fiona P. (1)
- Hills, Susan (3)
- Hills, Susan L. (1)
- Hutton, David W. (3)
- Janusz, Cara (1)
- Jeon, Seonghye (1)
- Jones, Jefferson (1)
- Kilburn, Kelly (1)
- Kobayashi, Miwako (1)
- Kotton, Camille (1)
- Leidner, Andrew (1)
- Leidner, Andrew J. (1)
- Lindsey, Nicole P. (1)
- Link-Gelles, Ruth (2)
- Lloyd, Patricia (1)
- Loehr, James (1)
- Loehr, Jamie (3)
- Long, Sarah S. (1)
- Melgar, Michael (2)
- Meltzer, Martin I. (1)
- Moro, Pedro L. (1)
- Moulia, Danielle (1)
- Munjal, Iona (1)
- Nyamuswa, Christina (1)
- Ortega-Sanchez, Ismael (1)
- Ortega-Sanchez, Ismael R. (1)
- Panagiotakopoulos, Lakshmi (1)
- Payne, Amanda (1)
- Pike, Jamie (1)
- Prosser, Lisa A. (1)
- Roper, Lauren (1)
- Rose, Angela (1)
- Rubis, Amy (1)
- Saydah, Sharon (1)
- Schillie, Sarah F. (1)
- Shah, Melisa (1)
- Sohn, Wendy (1)
- Staples, J. Erin (1)
- Stoecker, Charles (1)
- Stokley, Shannon (2)
- Surie, Diya (1)
- Wallace, Megan (1)
- Wong, Joshua (1)
- Zhou, Fangjun (1)
- Centers for Disease Control and Prevention (U.S.) (3)
- GSK Vaccines. (2)
- Marshfield Clinic Research Institute (1)
- Moderna (firm) (1)
- National Center for Emerging and Zoonotic Infections (U.S.). Division of Vector-Borne Diseases. Dengue Branch. (1)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. (1)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases. Arboviral Diseases Branch. (3)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. (1)
- National Center for Emerging Zoonotic and Infectious Diseases (U.S.) (1)
- National Center for Immunization and Respiratory Diseases (U.S.) (4)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. (3)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Surveillance and Prevention Branch. RESP-NET Hospitalization Surveillance Team. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Vaccine Effectiveness Program. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. Applied Research, Implementation Science and Evaluation Branch. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. (2)
- National Center for Immunizations and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. (1)
- National Center for Immunizations and Respiratory Diseases (U.S.). Immunization Services Division. (2)
- Pfizer Ltd. (1)
- Sanofi AstraZeneca (1)
- Tulane University. School of Public Health and Tropical Medicine. (1)
- United States. Advisory Committee on Immunization Practices. (3)
- United States. Advisory Committee on Immunization Practices. ACIP COVID-19 Vaccines Work Group. (1)
- United States. Advisory Committee on Immunization Practices. Adult RSV Work Group. (3)
- United States. Advisory Committee on Immunization Practices. Chikungunya Vaccines Work Group. (4)
- United States. Advisory Committee on Immunization Practices. Hib/Meningococcal Vaccines Work Group. (2)
- United States. Advisory Committee on Immunization Practices. HPV Vaccines Work Group. (1)
- United States. Advisory Committee on Immunization Practices. Influenza Work Group. (1)
- United States. Advisory Committee on Immunization Practices. Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group. (2)
- United States. Advisory Committee on Immunization Practices. Meningococcal/Hib Vaccines Work Group. (1)
- United States. Advisory Committee on Immunization Practices. Pneumococcal Vaccine Work Group. (1)
- United States. Food and Drug Administration. Center for Biologics Evaluation and Research. Office of Biostatistics and Pharmacovigilance. (1)
- University of Michigan. COVID-19 Vaccination Modeling Team. (1)
- University of Michigan. School of Public Health. (2)
- :Munjal, IonaJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:02-RSV-Adult-Munjal-508.pdf
- :Kilburn, Kelly ;Meltzer, Martin I.June 26, 2024 | ACIP meeting Chikungunya Vaccines Work Group:First slide dated "June 27th, 2024".04-Chikungunya-Kilburn-508.pdf
- :Kotton, CamilleJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:01-RSV-Adult-Kotton-508.pdf
- :Wong, JoshuaJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:02-Dengue-Wong-508.pdf
- :Bergren, NicholasJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:Dengue Tetravalent Vaccine (Live, Attenuated) [Dengvaxia®] is being discontinued due to low demand.This decision is not due to any concerns regarding...
- :Hills, SusanJune 26, 2024 | ACIP meeting Chikungunya Vaccines Work Group:05-Chikungunya-Hills-508.pdf
- :Donahue, JimJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:05-RSV-Adult-Donahue-508.pdf
- :Das, RituparnaJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:04-RSV-Adult-Das-508.pdf
- :Lloyd, PatriciaJune 26, 2024 | ACIP meeting Respiratory Syncytial Virus Vaccines – Adult:06-RSV-Adult-Lloyd-508.pdf
- :Panagiotakopoulos, LakshmiJune 27, 2024 | ACIP meeting COVID-19 Vaccines:06-COVID-Panagiotakopoulos-508.pdf
- :Link-Gelles, RuthJune 27, 2024 | ACIP meeting COVID-19 Vaccines:03-COVID-Link-Gelles-508.pdf
- :Prosser, Lisa A. ;Hutton, David W.June 27, 2024 | ACIP meeting COVID-19 Vaccines:05-COVID-Prosser-508.pdf
- :Duffy, JonathanJune 27, 2024 | ACIP meeting COVID-19 Vaccines:04-COVID-Duffy-508.pdf
- :Stokley, ShannonJune 27, 2024 | ACIP meeting COVID-19 Vaccines:07-COVID-Stokely-508.pdf
- :Havers, Fiona P.June 27, 2024 | ACIP meeting COVID-19 Vaccines:02-COVID-Havers-508.pdf
- :Dugan, Vivien G.June 27, 2024 | ACIP meeting Influenza Vaccines:02-influenza-dugan-508.pdf
- :Daley, Matthew F.June 27, 2024 | ACIP meeting COVID-19 Vaccines:01-COVID-Daley-508.pdf
- :Loehr, JamieJune 27, 2024 | ACIP meeting Influenza Vaccines:01-inlfuenza-loehr-508.pdf
- :Stoecker, CharlesJune 27, 2024 | ACIP meeting Pneumococcal Vaccines:02-Pneumococcal-Stoecker-508.pdf
- :Kobayashi, MiwakoJune 27, 2024 | ACIP meeting Pneumococcal Vaccines:04-Pneumococcal-Kobayashi-508.pdf
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.